Back to top
more

BeiGene, Ltd. (BGNE)

(Delayed Data from NSDQ)

$130.59 USD

130.59
151,729

+3.75 (2.96%)

Updated May 3, 2019 04:00 PM ET

After-Market: $130.61 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Waters Stock Gains on Earnings & Sales Beat in Q3, Raised View

by Zacks Equity Research

WAT's third-quarter 2024 results show growth in the pharma and industrial sectors. A dip in China sales creates headwinds.

Zacks Equity Research

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Zacks Equity Research

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Zacks Equity Research

BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last?

by Zacks Equity Research

BeiGene (BGNE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Wall Street Analysts See a 27.84% Upside in BeiGene (BGNE): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 27.8% upside potential for BeiGene (BGNE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

BeiGene, Ltd. (BGNE) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Is it a good or bad thing when a stock experiences a golden cross technical event?

Zacks Equity Research

Wall Street Analysts See a 40.85% Upside in BeiGene (BGNE): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 40.9% upside potential for BeiGene (BGNE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Argenx (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar?

by Zacks Equity Research

Travere (TVTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study

by Zacks Equity Research

Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.